• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Oncorus Inc.

    8/7/23 6:52:07 AM ET
    $ONCR
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $ONCR alert in real time by email
    DEFA14A 1 oncr_-_defa14a_8.7.23.htm DEFA14A DEFA14A

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

    ______________________

     

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    (Amendment No.__)

    ______________________

    Filed by the Registrant ☒

    Filed by a Party other than the Registrant ☐

    Check the appropriate box:

    ☐ Preliminary Proxy Statement

    ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

    ☐ Definitive Proxy Statement

    ☒ Definitive Additional Materials

    ☐ Soliciting Material Pursuant to § 240.14a-12

    ONCORUS, INC.

    (Name of Registrant as Specified In Its Charter)

    (Name of Person(s) Filing Proxy Statement if other than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

    ☒ No fee required.

    ☐ Fee paid previously with preliminary materials

    ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     

     

     


     

    img226316782_0.jpg 

     

    img226316782_1.jpg 

     

     

     

    August 4, 2023

     

    Address1

    Address2

    Address3

    Address4

    Address5

    Address6

    Address7

    Barcode

     

    URGENT – YOUR PARTICIPATION IS REQUIRED!

     

    Insert QR CODE here

     

    Re: Your investment in Oncorus, Inc.

     

    Dear Stockholder,

     

    We have been trying to reach you on behalf of Oncorus, Inc. We are acting as proxy solicitor for Oncorus’ Special Meeting of Stockholders, which has been adjourned until August 18th, 2023, to give stockholders additional time to cast their votes.

     

    The Special Meeting has been called to vote on the dissolution and liquidation of Oncorus. You are eligible to vote at the Special Meeting because you held Oncorus common stock as of the record date for the Special Meeting, June 8, 2023. You are eligible to vote even if you do not hold Oncorus common stock today. The company will not be in a position to make cash distributions unless and until the dissolution proposal is approved by stockholders of record. Please refer to the previously distributed proxy materials for disclosures regarding the dissolution proposal, estimated distributions to stockholders following dissolution and assumptions underlying such estimates. The proxy materials are available on the SEC’s website at www.sec.gov.

     

    Please contact us immediately at 1-855-601-2246 between the hours of 9:00am and 10:00pm Eastern time, Monday through Friday and Saturday and Sunday from 10:00am to 6:00pm or please scan the QR Code above and follow the prompts provided to vote your account. You may also email us at [email protected].

     

    This matter is very important and will only take a moment of your time.

     

    Thank you in advance for your assistance with this matter.

     

    Sincerely,

    Gina Balderas

    Operations Manager

     


    Get the next $ONCR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ONCR

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ONCR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Oncorus Announces Workforce Reduction Plan

      ANDOVER, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Oncorus, Inc. (NASDAQ:ONCR), an RNA medicines company focused on developing intravenously administered, self-amplifying RNA to transform outcomes for cancer patients, today announced that, in response to challenges associated with raising additional capital and pursuing strategic alternatives to secure additional funding, including current market conditions, the Company's board of directors has approved a workforce reduction of approximately 55 employees, representing substantially all of Oncorus' workforce, which is expected to be completed by August 2023. Theodore (Ted) Ashburn, M.D., Ph.D. (Chief Executive Officer), Stephen W. Harbin (C

      6/1/23 4:05:00 PM ET
      $ONCR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Oncorus Reports First Quarter 2023 Financial Results and Provides Business Updates

      IND submission for ONCR-021 still planned for mid-2023, subject to receipt of additional funding Ended the quarter with $45.0 million in cash, cash equivalents and investments ANDOVER, Mass., May 22, 2023 (GLOBE NEWSWIRE) -- Oncorus, Inc. (NASDAQ:ONCR), an RNA medicines company focused on developing intravenously administered, self-amplifying RNA to transform outcomes for cancer patients, today reported first quarter financial results and provided an update on its business. "Oncorus is pioneering a first-of-its-kind, self-amplifying RNA platform with an exciting lead program, ONCR-021, with plans to submit an IND with the FDA in mid-2023," said Theodore (Ted) Ashburn, M.D., Ph.D., Pres

      5/22/23 4:05:00 PM ET
      $ONCR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Oncorus Announces Research Collaboration with Daewoong Pharmaceutical for the Development of Lipid Nanoparticle Formulations for mRNA Drug Candidates

      Research collaboration leverages Oncorus' proprietary ionizable amines, PEG lipids, LNP formulations, process development and manufacturing together with Daewoong's mRNA expertiseOpportunity for future license, manufacturing and supply agreement for formulated drug candidates ANDOVER, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Oncorus, Inc. (NASDAQ:ONCR), an RNA medicines company focused on developing intravenously administered, self-amplifying RNA to transform outcomes for cancer patients, and Daewoong Pharmaceutical Co., Ltd. (KRX: 069620), a leading South Korean pharmaceutical company, today announced a research collaboration for the discovery and development of novel lipid nanoparticle

      1/4/23 7:00:00 AM ET
      $ONCR
      Medicinal Chemicals and Botanical Products
      Health Care

    $ONCR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Oncorus Inc. (Amendment)

      SC 13G/A - Oncorus, Inc. (0001671818) (Subject)

      2/14/23 8:02:36 AM ET
      $ONCR
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by Oncorus Inc. (Amendment)

      SC 13G/A - Oncorus, Inc. (0001671818) (Subject)

      2/13/23 12:36:32 PM ET
      $ONCR
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by Oncorus Inc. (Amendment)

      SC 13G/A - Oncorus, Inc. (0001671818) (Subject)

      2/2/23 2:15:07 PM ET
      $ONCR
      Medicinal Chemicals and Botanical Products
      Health Care

    $ONCR
    Leadership Updates

    Live Leadership Updates

    See more
    • Oncorus Reports First Quarter 2023 Financial Results and Provides Business Updates

      IND submission for ONCR-021 still planned for mid-2023, subject to receipt of additional funding Ended the quarter with $45.0 million in cash, cash equivalents and investments ANDOVER, Mass., May 22, 2023 (GLOBE NEWSWIRE) -- Oncorus, Inc. (NASDAQ:ONCR), an RNA medicines company focused on developing intravenously administered, self-amplifying RNA to transform outcomes for cancer patients, today reported first quarter financial results and provided an update on its business. "Oncorus is pioneering a first-of-its-kind, self-amplifying RNA platform with an exciting lead program, ONCR-021, with plans to submit an IND with the FDA in mid-2023," said Theodore (Ted) Ashburn, M.D., Ph.D., Pres

      5/22/23 4:05:00 PM ET
      $ONCR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Oncorus Appoints Douglas Fambrough to Board of Directors

      -Former CEO of Dicerna brings deep expertise in RNA research, drug development, business development and financing- CAMBRIDGE, Mass., June 23, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (NASDAQ:ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced the appointment of Douglas M. Fambrough, III, Ph.D. to its board of directors. "We are thrilled to welcome Doug to our board and leverage his significant expertise and executive leadership skills as we work to advance our next-generation HSV and selectively self-amplifying vRNA/LNP platforms," said Theodore (Ted) Ashburn, M.D., Ph.D., President and Chief Executive Officer

      6/23/22 7:00:00 AM ET
      $ONCR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Oncorus Announces Appointment of Richard Wanstall as Chief Financial Officer

      CAMBRIDGE, Mass., May 10, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (NASDAQ:ONCR), a viral immunotherapy company focused on driving innovation to transform outcomes for cancer patients, today announced the appointment of Richard Wanstall as Chief Financial Officer. "We are pleased to welcome Rick as our Chief Financial Officer and we look forward to drawing from his notable experience leading biotech companies through significant organizational growth," said Theodore (Ted) Ashburn, M.D., Ph.D., President and Chief Executive Officer of Oncorus. "Rick is a trusted colleague that I, as well as other members of the senior leadership team, have had the pleasure of working alongside in our previ

      5/10/22 7:00:00 AM ET
      $ONCR
      Medicinal Chemicals and Botanical Products
      Health Care

    $ONCR
    Financials

    Live finance-specific insights

    See more
    • Oncorus Announces Portfolio Reprioritization to Focus on IV-Administered, Self-Amplifying RNA Medicines for Patients with Cancer

      Company now focused on the development of ONCR-021, Oncorus' lead self-amplifying RNA product candidate for non-small cell lung and other cancers; program remains on track for IND submission in mid-2023Phase 1 clinical trial of ONCR-177 in patients with advanced disease is being discontinuedPrioritization of ONCR-021 and reduction in workforce reduces company's cash burn rate; Oncorus reiterates guidance of cash runway into early 2024 ANDOVER, Mass., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (NASDAQ:ONCR), an RNA medicines company focused on developing IV administered, self-amplifying RNA to transform outcomes for cancer patients, today announced that it is reprioritizing its pipeli

      11/30/22 7:00:00 AM ET
      $ONCR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Oncorus Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates

      Data presented from ongoing Phase 1 clinical trial of ONCR-177 in multiple solid tumor indications at RP2D at SITC 2021 and preclinical studies of ONCR-GBM targeting brain cancer at IOVC 2021Signed exclusive licensing agreement with Gaeta Therapeutics for use of locally delivered IL-12 via oncolytic viral expression in combination with immune checkpoint inhibitorsAdditional clinical data from ONCR-177 surface lesion monotherapy expansion and combination expansion cohorts expected in second half of 2022Continued to advance preclinical programs, including ONCR-021 towards IND filing in mid-2023Strengthened executive leadership team with promotion of John Goldberg, M.D., to Chief Medical Office

      3/9/22 7:00:00 AM ET
      $ONCR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Oncorus Reports Initial Safety, Tolerability, Immune Activation and Positive Clinical Response Data from its Ongoing Phase 1 Clinical Study of ONCR-177, its Lead Viral Immunotherapy Candidate, at SITC 2021

      ONCR-177 was well tolerated with no dose-limiting toxicities in the surface lesion dose escalation part of the first-in-human study in heavily pretreated patients with advanced, injectable solid tumorsRecommended Phase 2 dose (RP2D) selected and expansion monotherapy cohort dosing is underwayThree of eight evaluable patients at RP2D across multiple indications (cutaneous melanoma, head and neck cancer, and mucosal melanoma) experienced clinical benefit after two doses of single-agent ONCR-177Proof of principle established for propriety Herpes Simplex Virus (HSV) platform that leverages microRNA attenuation to enable interferon resistance via retention of γ34.5 and five complementary immunomo

      11/12/21 7:00:00 AM ET
      $ONCR
      Medicinal Chemicals and Botanical Products
      Health Care

    $ONCR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Maxim Group initiated coverage on Oncorus with a new price target

      Maxim Group initiated coverage of Oncorus with a rating of Buy and set a new price target of $35.00

      3/16/21 7:41:50 AM ET
      $ONCR
      Medicinal Chemicals and Botanical Products
      Health Care

    $ONCR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3: New insider Shea Brian J. claimed ownership of 8,541 shares

      3 - Oncorus, Inc. (0001671818) (Issuer)

      6/16/23 9:20:42 AM ET
      $ONCR
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 3 filed by new insider Nolte Alexander

      3 - Oncorus, Inc. (0001671818) (Issuer)

      5/22/23 5:00:27 PM ET
      $ONCR
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 4: Flynn James E sold $88,254 worth of shares (336,235 units at $0.26)

      4 - Oncorus, Inc. (0001671818) (Issuer)

      12/30/22 7:16:31 PM ET
      $ONCR
      Medicinal Chemicals and Botanical Products
      Health Care

    $ONCR
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Oncorus Inc.

      DEFA14A - Oncorus, Inc. (0001671818) (Filer)

      8/7/23 6:52:07 AM ET
      $ONCR
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 15-12G filed by Oncorus Inc.

      15-12G - Oncorus, Inc. (0001671818) (Filer)

      8/3/23 5:00:26 PM ET
      $ONCR
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form DEFA14A filed by Oncorus Inc.

      DEFA14A - Oncorus, Inc. (0001671818) (Filer)

      7/28/23 4:40:36 PM ET
      $ONCR
      Medicinal Chemicals and Botanical Products
      Health Care